文献速递皮肤肿瘤

新型黑色素瘤疗法对死亡率影响的地理差异

Geographic variation in the impact of novel melanoma therapies on mortality.
PubMed 文献 · J Am Acad Dermatol · 2026-03-09

该重复横断面生态研究利用SEER县级别死亡率数据,评估2008-2013至2019-2023年间新型免疫与靶向疗法引入后黑色素瘤死亡率下降的县际差异。全国死亡率下降25.6%,751个县降幅中位数23.8%(四分位距7.6%-35.6%),县人口规模是最强预测因子(β=4.5,95%CI 1.6-7.4,P=.002)。

要点

  • 全国黑色素瘤死亡率下降25.6%,但县际差异大(中位23.8%,四分位距7.6%-35.6%)。
  • 县人口规模是死亡率下降的最强预测因子(β=4.5,95%CI 1.6-7.4,P=.002)。
  • 若所有县达到最大县的降幅,可额外避免2818例死亡。

核心结论

  • 县人口规模强烈预测新型黑色素瘤疗法带来的死亡率获益,提示需加强医疗基础设施以减少地理差异。

研究设计与样本

  • 重复横断面生态研究,使用SEER项目县级别死亡率数据,比较2008-2013与2019-2023两个时期。
  • 纳入751个县,县特征来自Area Health Resource File、美国医院协会调查、Medicare索赔和National Provider Identifier数据库。
  • 采用普通最小二乘回归评估关联。

主要发现

  • 全国黑色素瘤死亡率在2008-2013至2019-2023年间下降25.6%。
  • 751个县的死亡率降幅中位数为23.8%,四分位距为7.6%至35.6%。
  • 县人口规模是死亡率下降的最强预测因子(β=4.5;95%CI 1.6-7.4;P=.002)。
  • 若所有县达到最大县的死亡率降幅,可额外避免2818例死亡。

关键数值与推荐

  • 主要结局为2008-2013至2019-2023年间年龄调整黑色素瘤死亡率的百分比变化。
  • 县人口规模与死亡率下降的回归系数β=4.5(95%CI 1.6-7.4,P=.002)。

临床怎么用

  • 临床与公共卫生层面应关注小县医疗资源不足,强化基础设施以缩小新型疗法获益的地理差异。

局限性

  • 生态设计及依赖聚合数据限制因果推断和个体水平解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel immunotherapies and targeted therapies have transformed melanoma treatment, but the geographic distribution of benefits remains unclear. OBJECTIVE: To quantify county-level variation in melanoma mortality declines following the introduction of novel therapies and identify associated patient and health system factors. METHODS: We conducted a repeated cross-sectional ecological study using county-level mortality data from the Surveillance, Epidemiology, and End Results Program. The primary outcome was percent change in age-adjusted melanoma mortality between 2008-2013 and 2019-2023. County characteristics were obtained from the Area Health Resource File, American Hospital Association Survey, Medicare claims, and National Provider Identifier database. Associations were assessed using ordinary least squares regressions. RESULTS: National melanoma mortality declined 25.6% between 2008-2013 and 2019-2023. Across 751 counties, declines varied widely (median, 23.8%; interquartile range, 7.6% to 35.6%). County population size was the strongest predictor of mortality decline (β = 4.5; 95% confidence interval, 1.6-7.4; P = .002). Had all counties achieved the mortality reductions of the largest counties, 2818 additional deaths could have been prevented. LIMITATIONS: Ecological design and reliance on aggregates limit causal inference and individual-level interpretation. CONCLUSIONS: Population size strongly predicts mortality benefits from novel melanoma therapies, underscoring the importance of strengthening health care infrastructure to reduce geographic disparities.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Kong EL, Sullivan R, Tsao H, et al. Geographic variation in the impact of novel melanoma therapies on mortality. J Am Acad Dermatol. 2026. PMID: 41812981. doi:10.1016/j.jaad.2026.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。